Global Immunoassay Market Projected to Reach US$ 55.9 Billion by 2034, Growing at 5.2% CAGR
核心洞察
The global immunoassay (搜索) market is expected to grow from US$ 37.7 billion in 2024 to US$ 55.9 billion by 2034, at a CAGR of 5.2% during 2025–2034.
North America dominated the market in 2024, capturing more than 43.4% share and a valuation of US$ 14.6 billion, driven by advanced healthcare infrastructure and diagnostic adoption.
Rising cancer (搜索), diabetes (搜索), cardiovascular, and infectious disease burdens are fueling demand, with WHO reporting 20 million new cancer cases and 9.7 million cancer deaths globally in 2022.
The global immunoassay (搜索) market is projected to expand from US$ 37.7 billion in 2024 to approximately US$ 55.9 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2034. North America held a dominant market position in 2024, capturing more than a 43.4% share and reaching a valuation of US$ 14.6 billion.
The market's steady growth is supported by rising demand for accurate and rapid diagnostic testing across hospitals, laboratories, and research institutions. Immunoassays leverage antigen–antibody interactions to detect hormones, proteins, infectious agents, and other biomarkers with high sensitivity and specificity. Technologies such as ELISA, chemiluminescent immunoassays (CLIA), and radioimmunoassays are widely used in disease diagnosis, pharmaceutical research, food safety, and environmental monitoring.
Disease Burden Driving Diagnostic Demand
The increasing prevalence of cancer (搜索) is a major factor driving market expansion. According to the World Health Organization (WHO), around 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. The International Agency for Research on Cancer (IARC) also reported that lung cancer accounted for 12.4% of new cancer cases and 18.7% of global cancer deaths in 2022, reinforcing the need for reliable biomarker-based diagnostic testing.
The growing burden of chronic diseases is further boosting adoption of immunoassays. WHO reported that 43 million people died from noncommunicable diseases (NCDs) in 2021, representing 75% of all non-pandemic deaths. Cardiovascular diseases (搜索) caused 19 million deaths, while cancers accounted for 10 million deaths. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that 38.4 million people are living with diabetes (搜索), increasing demand for routine HbA1c and related immunoassay (搜索)-based tests.
Infectious disease testing also remains a major application. WHO estimated 39.9 million people were living with HIV (搜索) globally at the end of 2023, while an estimated 254 million people were living with chronic hepatitis B (搜索) infection in 2022 and 50 million with chronic hepatitis C (搜索). WHO further reported that 10.8 million people developed tuberculosis (搜索) in 2023, and 49 million people develop sepsis (搜索) each year, resulting in approximately 11 million deaths.
Market Segmentation
By product type, reagents and kits dominated the segment in 2024, accounting for more than 67.0% of total market share due to their extensive use in diagnostic and research applications. Enzyme immunoassays (EIA) led the technology segment in 2024, capturing over 60.5% market share, supported by their high efficiency and broad clinical adoption.
Infectious disease testing held the largest application share in 2024, representing more than 36.3% of the market. Blood specimens emerged as the leading specimen type, contributing over 44.2% of the market owing to their widespread use in routine immunoassay (搜索) testing. Pharmaceutical and biotechnology companies accounted for the largest end-user share in 2024, holding more than 31.7% of the market, supported by expanding research and drug development activities.
Regional Leadership and Growth
North America retained the largest regional share in 2024, accounting for more than 43.4% of the market and reaching a value of US$ 14.6 billion. The region benefits from a well-established healthcare system, advanced laboratory infrastructure, and widespread adoption of automated diagnostic technologies. According to the U.S. CDC, approximately 38.4 million Americans are living with diabetes (搜索), while the American Cancer (搜索) Society estimated nearly 2.0 million new cancer cases in the United States in 2024.
Government agencies, including the U.S. Food and Drug Administration (搜索) (FDA), continue to approve innovative in vitro diagnostic products, accelerating technology adoption. Strong investments in biotechnology research, precision medicine, and clinical diagnostics, supported by organizations such as the National Institutes of Health (NIH), are driving product innovation.
Emerging Trends and Technological Advancements
Point-of-care (POC) immunoassays are expanding rapidly as healthcare providers seek faster diagnosis outside traditional laboratories. The U.S. FDA notes that the number of at-home and POC diagnostic tests increased significantly following the COVID-19 pandemic, with digital connectivity becoming an important feature for real-time clinical decision-making.
Regulatory oversight is strengthening to improve diagnostic accuracy. In 2024, the FDA introduced new regulatory requirements for laboratory-developed tests (LDTs), while noting that around 70% of healthcare decisions rely on laboratory test results. WHO also updated its tuberculosis (搜索) diagnostic target product profiles in 2024, introducing new performance requirements for point-of-care and near-point-of-care tests.
Automation and high-throughput laboratory platforms are increasingly adopted by hospitals and diagnostic laboratories to improve efficiency and reduce turnaround time. The integration of immunoassay (搜索) platforms with digital health systems is improving reporting and patient monitoring, highlighted by the FDA's 2023 TOPx Diagnostic Data Exchange Sprint, which involved 17 innovation teams and experts from FDA, NIH, CDC, and ONC.
Outlook
The global immunoassay (搜索) market is positioned for steady growth due to increasing demand for accurate, rapid, and sensitive diagnostic solutions. Rising cases of cancer (搜索), diabetes (搜索), cardiovascular diseases (搜索), and infectious disorders are driving the need for advanced immunoassay-based testing. With growing emphasis on early disease detection, precision medicine, and preventive healthcare, immunoassays are expected to remain a critical component of modern diagnostics and clinical decision-making.